Previous Close | 0.2800 |
Open | 0.3000 |
Bid | 0.2900 x 0 |
Ask | 0.3000 x 0 |
Day's Range | 0.2900 - 0.3000 |
52 Week Range | 0.2700 - 0.5000 |
Volume | 33,000 |
Avg. Volume | 31,465 |
Market Cap | 22.427M |
Beta (3Y Monthly) | 2.00 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0110 |
Earnings Date | Nov. 13, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Gilles Gagnon has been the CEO of Ceapro Inc. (CVE:CZO) since 2012. This analysis aims first to contrast CEO...
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Maintained R&D focus on the development of delivery.
OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the European and U.S. Patent and Trademark Offices have issued the Company European Patent No. 2411527 and U.S. Patent No. 10,334,869 entitled, “Method For Increasing Concentration of Avenanthramides in Oats,” related to the production of its value-driver product, avenanthramides, utilizing a malting technology in-licensed from Agriculture and Agri-Food Canada. Ceapro's flagship product, avenanthramides, is a group of phenolic alkaloids compounds uniquely found in oats and produced using a proprietary patented process.
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its common shares have been approved for trading onto the OTCQX® Best Market, a U.S. market that is operated by the OTC Markets Group in New York.
Ceapro Inc. (CVE:CZO) shareholders should be happy to see the share price up 13% in the last quarter. But only the...
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that during a podium presentation, Dr. Bernhard Seifried, Senior Director, Engineering Research & Technologies at Ceapro, will present at the 3rd International Symposium on Pharmaceutical Engineering Research (“SPhERe”) being held September 25-27, 2019 in Braunschweig, Germany.
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will present at the Fall Investor Summit on Monday, September 16, 2019 at 2:30 PM EDT in New York, NY. For more information about the conference, please click here to visit the conference website.
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Increased R&D investment focused on the development.
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) has awarded a $670,315 Collaborative Health Research Projects (CHRP) Initiative grant for a three-year collaborative project with Dr. Todd Hoare, Dr. Brian Coombes and Dr. Kjetil Ask at McMaster University. This project marks the beginning of the second phase of an extensive research program initiated in March 2016 with researchers at McMaster University under Dr. Hoare’s leadership.
If you own shares in Ceapro Inc. (CVE:CZO) then it's worth thinking about how it contributes to the volatility of your...
EDMONTON, Alberta, Aug. 15, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
If you want to know who really controls Ceapro Inc. (CVE:CZO), then you'll have to look at the makeup of its share...
EDMONTON, Alberta, June 10, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
Ceapro Inc. (CZO.V) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented very promising data from its collaboration study of the immunoregulatory effect of oat avenanthramides during downhill running in young men and women at the Annual World Congress of the American College of Sports Medicine (ACSM), held May 28-June 1, 2019 in Orlando, Florida. The Company previously announced positive results on the anti-inflammatory properties of avenanthramides at the American Society for Nutrition’s inaugural flagship meeting, Nutrition 2018, which showed that oat avenanthramides supplementation reduces circulatory inflammation and inhibits expressions of chemokines and adhesion molecules.
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has commenced patient enrollment in its comparison study evaluating high-medium molecular weight beta glucan as an add-on therapy to statins in subjects with hyperlipidemia. “We are pleased with the progress of this important study and believe that it represents a significant milestone for the Company as we continue our transition towards becoming a biopharmaceutical company.
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Increased R&D investment focused on the development.
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that both of its two Alberta-based bioprocessing plants, located in Leduc and Edmonton, have received a Site License from the Health Canada Natural and Non-Prescription Health Products Directorate. This license enables the Company to fabricate, package, label, release and distribute final products.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Gilles Gagnon became the CEO of Ceapro Inc. (CVE:CZO) in 2012. This report will, first, ex...
EDMONTON, Alberta, April 24, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
EDMONTON, Alberta, April 15, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
– 2018 marked by Company’s catalytic pivot from contract manufacturer tobiopharmaceutical company and validation of Ceapro’s dedication to innovation – EDMONTON, Alberta, April.
EDMONTON, Alberta, March 27, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Office of the Controller General of Patents, Design and Trademarks, India has issued the Company Patent No. 305103 entitled, “Supercritical Fluid Treatment of High Molecular Weight Biopolymers,” related to its Pressurized Gas eXpanded (“PGX”) technology.
EDMONTON, Alberta, Feb. 26, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of stock options (“options”) and restricted share units (“RSUs”) to all employees, officers and directors of the Company. Options to purchase 420,000 common shares were granted pursuant to the Company’s Stock Option Plan, with an exercise price of $0.38.5 per common share. Each grant vests in three equal instalments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant.